Stockscreener 앱 받기
2.60
4.84%
0.12
시간 외 거래:
2.60
전일 마감가:
$2.48
열려 있는:
$2.5
하루 거래량:
46,566
Relative Volume:
0.36
시가총액:
$20.78M
수익:
-
순이익/손실:
$-20.84M
주가수익비율:
-0.3526
EPS:
-7.3739
순현금흐름:
$-18.59M
1주 성능:
+1.17%
1개월 성능:
-1.14%
6개월 성능:
-20.97%
1년 성능:
-41.18%
1일 변동 폭
$2.50
$2.6363
1주일 범위
$2.45
$2.65
52주 변동 폭
$2.20
$6.52
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.60 | 20.78M | 0 | -20.84M | -18.59M | -7.3739 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake - Stock Titan
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar - TipRanks
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Cellectar Biosciences (CLRB) investor discloses 9.99% stake via stock and warrants - Stock Titan
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants - Stock Titan
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake - Stock Titan
Cellectar Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens - Investing.com
CLRB: Positive clinical results, robust financing, and regulatory momentum drive pipeline advancement - TradingView
Cellectar Biosciences Q2 2026 Earnings Call Transcript - Benzinga
Cellectar Q2 net loss widens 28% to $6.9M, misses EPS estimate - scanx.trade
Cellectar Biosciences reports Q2 2026 net loss $6.9M, cash $34.0M; advances iopofosine Phase 3 - TradingView
CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM - TradingView
Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M - Stock Titan
Cellectar Biosciences Q2 net loss widens on higher R&D costs - TradingView
Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing - Stock Titan
Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary - TradingView
Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk - Stock Titan
Cellectar Biosciences (CLRB) Earnings Date and Reports 2026 $CLRB - marketbeat.com
Cellectar Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Empery Asset Management, LP Initiates Position in Cellectar Bios - GuruFocus
Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured - Stock Titan
Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18 - Stock Titan
Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13. - Moomoo
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants - Stock Titan
Cellectar Biosciences to Report Second Quarter Financial - GlobeNewswire
Cellectar Biosciences to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 13 - Quiver Quantitative
Cellectar Biosciences (CLRB) Edges Higher Amid Low Volume; Key Support and Resistance in FocusEquity Put Call - dars.gov.et
Cellectar Biosciences (CLRB) Edges Higher as Volume Picks Up at Critical JunctureDark Pool Volume - dars.gov.et
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLRB|Cellectar Biosciences Inc|Price:2.410|Chg%:-0.060 - TradingKey
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Cellectar Biosciences Inc (CLRB) Balance Sheet - TradingKey
Cellectar Biosciences Inc (CLRB) Cash Flow - TradingKey
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
Cellectar Publishes Phase 1 Iopofosine Data - t.co
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - Sahm
Cellectar publishes phase 1 data on multiple myeloma treatment By Investing.com - Investing.com South Africa
Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Cellectar publishes phase 1 data on multiple myeloma treatment - Investing.com
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):